Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

3 recruiting2 with results

Enrollment Performance

Analytics

Phase 2

5(55.6%)

Phase 1

4(44.4%)

9Total

Phase 2(5)

Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT02799485Phase 2Completed

sEphB4-HSA in Treating Patients With Kaposi Sarcoma

Role: collaborator

NCT02495896Phase 1Active Not Recruiting

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

Role: collaborator

NCT06493552Phase 2Recruiting

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

Role: lead

NCT04091867Phase 1Completed

sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC

Role: collaborator

NCT03993106Phase 2Recruiting

A Study of sEphB4-HSA in Kaposi Sarcoma

Role: lead

NCT04486781Phase 2Recruiting

A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma

Role: lead

NCT01642342Phase 1Terminated

Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors

Role: collaborator

NCT04033432Phase 2Unknown

sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Role: collaborator

NCT03519984Phase 1Terminated

EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia

Role: collaborator

All 9 trials loaded